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Introduction
Glycosyltransferases (GTs) are key enzymes for the biosynthesis of complex glycans and glycoconjugates in all domains of life [1] . In bacteria, GT activity is required for virulence and viability, and individual GTs are emerging as novel targets for antimicrobial and anti-virulence drug discovery [2, 3] . Small molecular inhibitors of GTs are therefore sought after as chemical tools for the interrogation, manipulation and disruption of cellular glycosylation pathways [4] , and as potential lead compounds for drug discovery. Most existing GT inhibitors are substrate analogues that are structurally derived from the respective GT donor and/or acceptor [5] . Such substrate-based GT inhibitors are usually not drug-like and often suffer from modest bioactivity and/or intrinsic physicochemical liabilities, such as limited stability and poor cell penetration.
While some of these drawbacks can be circumnavigated by using metabolic precursors [6] [7] [8] , the identification of alternative, non-substrate-like GT inhibitors remains an important goal in medicinal chemistry and chemical biology [9] . Despite recent progress [10, 11] , very few such non-substrate-like GT inhibitors are currently available, in stark contrast to other enzyme classes of similar size and biological importance (e.g. kinases, proteases).
Covalent enzyme inhibitors are currently undergoing a renaissance in chemical biology [12] and drug discovery [13] . Covalent inhibitors generally display a range of attractive features, including high potency, prolonged duration of action, and amenability to rational design. A systematic study has recently shown that even reactive electrophiles, such as the Michael acceptor acrylamide, do not react indiscriminately with any biological nucleophile [14] . This differential reactivity can be harnessed for the development of covalent inhibitors, especially those that target non-catalytic residues [15] . This approach has been used successfully for inhibitor development against several challenging enzyme targets, including drug-resistant kinases [16] and proteases [17] . The covalent targeting of non-catalytic residues, in particular cysteines, therefore represents a promising strategy for inhibitor development against intractable targets such as GTs. To date, no inhibitors with this mode of action have been reported for any bacterial GT. This is particularly striking, as non-catalytic cysteines are a common motif in the active site of bacterial GTs. Even beyond bacterial enzymes, there is only a single mechanistically related example in the entire GT family [11] . Inhibitors of the mammalian O-linked N-acetylglucosamine transferase (OGT) act via an unusual doubledisplacement mechanism, which draws on the unique architecture of this enzyme -not found in other GTs -and requires a very specific arrangement of two separate target residues [11] .
Herein, we describe a new class of non-substrate-like, covalent inhibitors of the retaining -1,4-galactosyltransferase LgtC from Neisseria meningitidis. LgtC catalyzes the transfer of D-galactose (D-Gal) from a UDP-Gal donor to a lactose acceptor (Fig. 1A ) [18] . In pathogenic Gram-negative bacteria such as Neisseria and Haemophilus, LgtC is required for the biosynthesis of the terminal digalactoside epitope -D-Galp-(1,4)--DGalp in the lipooligosaccharide (LOS) structures of the outer core of the cell envelope [19] . LgtC expression has been associated with high-level serum resistance in nontypeable Haemophilus influenzae (NTHi) [19] , and inhibition of LgtC and related GTs that are involved in LOS biosynthesis has been suggested as a strategy for antimicrobial drug discovery [18] . LgtC is an excellent starting point for such an approach not only because of its role in bacterial virulence, but also because of its structural and mechanistic communalities with other bacterial GTs [18] , which have made it a widely used model system for mechanistic and structural studies in this enzyme family.
We have identified small molecular inhibitors of LgtC that are structurally unrelated to both the LgtC donor and acceptor (Fig. 1B) . We demonstrate that these inhibitors act via a covalent mechanism of inhibition, targeting a non-catalytic cysteine residue in the LgtC active site. Analysis of sequence and structural data shows that active-site cysteines are a common feature in bacterial GTs. Our results may therefore serve as a blueprint for the rational development of non-substrate-like, covalent inhibitors of other bacterial enzymes in this family.
Figure 1
(A) The LgtC reaction, and its inhibition by pyrazol-3-one 1. a (B) Chemical structures of pyrazol-3-ones 1-3. a Assay conditions: LgtC (activated with 5 mM DTT), lactose (2 mM), UDP-Gal (28 µM), MnCl 2 (5 mM), CIP (10 U/ml), CEL (1 mg/ml), Triton (0.01%) and inhibitor (0.1-100 µM) were incubated in HEPES buffer (pH 7.0) for 20 min at 30 °C. The progress of the reaction was determined with malachite green as previously described [20] .
Results and discussion

Rationale and chemical synthesis of inhibitors.
We have recently adapted a biochemical GT assay for inhibitor studies with non-substrate-like chemotypes [20] . We have subsequently used this assay to evaluate a collection of 130 small molecules as potential non-substrate-like inhibitors of LgtC. The collection was designed around structural scaffolds that are known from other GT inhibitors, including nucleosides, steroids, and pyrazol-3-ones (Fig. 1B) . Pyrazol-3-ones have previously been reported as screening hits against other GTs [21, 22] , but their molecular mode of action has not been investigated. From our own screen against LgtC, pyrazol-3-one 1 emerged as the most promising hit from this series and is the primary target molecule of the present study. 1 was synthesized in two steps from phenylhydrazine via a ring-closing condensation with ethyl acetoacetate, followed by a Knoevenagel condensation with 2-trifluoromethyl benzaldehyde (Scheme 1). This synthesis was readily adapted to also provide access to the congeners 2 and 3 (Scheme 1).
Scheme 1 Synthesis of target molecules 1-3.
a a Reagents & conditions: (i) ethyl 3-oxobutanoate, acetic acid, 110 ºC, 97% (6) or ethyl 4,4,4-trifluoroacetoacetate, acetic acid, 110 ºC, 72% (7); (ii) 2-(trifluoromethyl) benzaldehyde, acetic acid, reflux, 48% (for 1); (iii) 3-(benzyloxy)benzaldehyde (for 2) or 3-bromo-4-methoxybenzaldehyde (for 3), 160 o C/microwave, 15 min, 53% (2) or 75% (3)
Biochemical evaluation of inhibitors.
In initial experiments, pyrazol-3-one 1 inhibited LgtC with an IC 50 value of 27 μM (Fig. 1A) . All inhibition assays were carried out in the presence of surfactant to suppress non-specific aggregation and avoid assay artefacts [23] . This assay protocol provided confidence that the inhibitory activity of 1 was genuine. Equally importantly, 1 showed no inhibitory activity in control experiments
against the calf intestinal phosphatase (CIP) used as a secondary enzyme in the biochemical assay (SI).
We hypothesised that 1 may act as a covalent inhibitor towards LgtC, due to the presence of the Michael acceptor system, which is a known cysteine-reactive electrophile in covalent inhibitors and probes [24] . As no reports on pyrazol-3-ones as covalent enzyme inhibitors have previously been published, we set out to experimentally test this hypothesis. First, we compared enzyme activity in the assay mixture of LgtC and 1 before and after diafiltration. The inhibitory activity of 1 was preserved after diafiltration, which strongly suggested a covalent mode of inhibition (Fig. 2 ).
Figure 2
LgtC activity in the presence of inhibitor 1, before and after diafiltration. Conditions: LgtC (activated with 5 mM DTT) was pre-incubated with inhibitor (100 M) or DMSO, in the presence of UDP-Gal (28 µM), for 10 min at 30 °C. Lactose (2 mM) was added, and the reactions were incubated for 20 min at 30 °C. Samples were drawn, and enzyme activity before diafiltration was determined under standard assay conditions. Enzyme reactions (3 mL) were subjected to diafiltration in Vivaspin concentrator tubes (centrifugation at 4 °C, 4000 rpm). The initial residual volume (300 µL) was washed once with HEPES buffer (pH 7.0, total volume 3 mL). The residual volume (300 µL) from the wash step was diluted to 450 µL with HEPES buffer (pH 7.0), and enzyme activity after diafiltration was determined under standard assay conditions (2 mM lactose, 28 µM UDP-Gal, 20 min incubation at 30 °C). Each experiment was carried out in triplicate (100% activity = complete conversion of UDP-Gal). Error bars represent standard deviation.
Next, we directly analysed the reaction of LgtC with 1 by mass spectrometry.
These experiments showed the formation of a covalent adduct, providing direct evidence for the covalent reaction of 1 and LgtC (Fig. 3A) . Importantly, only a single adduct was observed in these experiments, at a 1:1 ratio of inhibitor and enzyme. This suggests that 1 reacts only with a single residue in LgtC. (Fig. 4 ), but not with L-serine or L-lysine (SI). These results show that under otherwise identical conditions, the Michael acceptor system in 1 reacts preferentially with a sulfur nucleophile.
This preference suggested that the target residue in LgtC may be a cysteine, although the reactivity of a specific residue in the environment of the protein will necessarily depend on neighboring groups. LgtC contains five cysteines, of which three are solvent-accessible [18] . One of these is Cys246, which sits at the interface of the LgtC acceptor and donor binding sites, in close proximity to the lactose acceptor (SI, Fig.   S1 ). Molecular simulations using a covalent docking protocol [25] suggested that 1 is binding at the substrate binding site of LgtC in an ideal orientation for the covalent reaction of the Michael acceptor system with Cys246 (SI, Fig. S1 ). In order to experimentally test the hypothesis that 1 may indeed bind at the substrate binding site, we investigated the effect the concentration of the LgtC acceptor, lactose, may have on inhibition. Under standard assay conditions (no pre-incubation, turnover 20-50%), inhibitory activity decreased markedly at higher acceptor concentrations (Fig. 5A ).
Qualitatively, this is consistent with an acceptor-competitive binding mode for 1. In order to obtain quantitative data and enable detailed enzyme kinetics analysis, we repeated this experiment at turnover rates of <10%, at a fixed concentration of UDP-Gal donor (100 M), and variable concentrations of lactose acceptor (5-25 mM) and inhibitor (1-5 M). Dixon and Cornish-Bowden analyses of the resulting data show that under these conditions, 1 acts as a competitive inhibitor of LgtC relative to the lactose acceptor (Fig. 5B ). These results show that 1 does indeed bind at the substrate binding site, as required for a potential covalent reaction with Cys246.
Figure 5
Effect of different acceptor concentrations on the inhibitory activity of pyrazol-3-one 1 towards LgtC under standard assay conditions (A) and enzyme kinetics conditions (B). 
Conditions: LgtC was incubated with 1 (1-5 µM), UDP-Gal (100 µM), MnCl 2 (5 mM), CIP (10 U/ml), CEL (1 mg/ml), Triton (0.01%) and lactose acceptor (5-25 mM) for 20 min at 30 °C in 13 mM HEPES buffer (pH 7.0). Data points were fitted to a Dixon or CornishBowden plot with GraFit 7.
In order to investigate the role of Cys246 for the inhibitory activity of 1, we created two LgtC mutants, in which Cys246 is replaced with a non-nucleophilic (C246A) or only weakly nucleophilic (C246S) residue. Both mutants were catalytically active under our standard conditions, albeit less so than wild-type LgtC. At the highest enzyme concentration tested, the observed turnover of donor was approximately 36% (C246A) or 22% (C246S) of that of the wild-type enzyme (SI). This level of enzymatic activity was sufficient for inhibition experiments. Under the standard assay conditions, pyrazol-3-one 1 at the highest concentration (100 μM) showed only weak inhibition against C246S
LgtC, and almost none against C246A LgtC (Fig. 6 ). These results provide direct evidence that Cys246 is a critical residue for the inhibition of LgtC by pyrazol-3-one 1, possibly as the target for a covalent interaction with the inhibitor. They also suggest that 1 is only weakly effective as a non-covalent inhibitor of LgtC, at least at the concentrations tested.
Figure 6
Compound 1 shows only weak inhibition of the LgtC mutants C246A and C246S. a a Conditions: LgtC was incubated with 1 (0.1-100 µM), UDP-Gal (28 µM), MnCl 2 (5 mM), CIP (10 U/ml), CEL (1 mg/ml), Triton (0.01%) and lactose acceptor (2 mM) for 20 min at 30 °C in 13 mM HEPES buffer (pH 7.0). Control experiments without inhibitor were carried out in parallel, showing a donor turnover of, respectively, 23% (wild-type), 21% or 39% (C246A), and 26% (C246S). Each experiment was carried out in triplicate.
To further dissect the structural requirements for the interaction between 1 and LgtC, we next carried out inhibition experiments with structural analogues of 1 (SI). As expected, compound 4, a hydrogenated variant of 1 lacking the exocyclic double bond and hence the capacity for covalent interaction, showed no inhibitory activity against LgtC (SI, Table S1 ). Compound 5, which contains a different heterocyclic scaffold, but the same Michael acceptor system as pyrazol-3-one 1, was also inactive (SI, Table S1 ).
The lack of activity of compounds 4 and 5 shows that the Michael acceptor system in 1 is necessary, but not sufficient, for the inhibition of LgtC. It suggests that non-covalent interactions also contribute to the LgtC inhibitory activity of 1, probably by orienting the inhibitor correctly in the substrate binding site prior to a covalent interaction with Cys246.
The substrate binding sites of GTs with the same donor and/or acceptor are highly conserved. We therefore decided to explore the behaviour of 1 against three other GTs (Table 1) , which use either the same UDP-Gal donor (bovine -1,4-GalT) or the same lactose acceptor (Pasteurella multocida α-2,3-SiaT, human FUT-2) as LgtC, but lack an active-site cysteine. Pyrazol-3-one 1 was inactive against all three of these GTs (Table 1 & SI) . These results demonstrate that 1 does not act simply as a non-covalent GT substrate mimic. Taken together, our results suggest strongly that it is the capacity to bind non-covalently at the substrate binding site of LgtC, in combination with a covalent interaction, most likely with Cys246, which forms the basis for the inhibitory activity of 1 towards LgtC. Having established that prototype pyrazol-3-one 1 does indeed act via a covalent mode of action, we set out to improve the potency of this new LgtC inhibitor class. To increase the reactivity of the Michael acceptor system, we replaced the 5-CH 3 group in 1 with a strongly electron-withdrawing 5-CF 3 group (Fig. 1B) . The exact 5-CF 3 congener of 1, bearing a (2-trifluoromethyl)benzylidene substituent in position 4, was not synthetically accessible. We therefore introduced alternative benzylidene substituents in position 4 (Fig. 1B) . While the new inhibitors 2 and 3 showed no, or only modest, activity under our standard assay conditions, their inhibitory activity increased markedly upon preincubation of LgtC with inhibitor, prior to starting the enzyme reaction ( Fig. 7 & 8) . Such a time-dependent inhibition is characteristic for a covalent mode of action. Interestingly, the pronounced effect of pre-incubation on inhibitory activity was largely independent of the presence of donor or acceptor substrate (Fig. 7, methods B-D) .
Figure 7
Pre-incubation with LgtC significantly increases the inhibitory activity of 2 and 3, both in the presence and absence of LgtC substrates. Table 2 ), LgtC was incubated with inhibitor (0.1-100 µM), UDP-Gal (28 µM), MnCl 2 (5 mM), CIP (10 U/ml), CEL (1 mg/ml), Triton (0.01%) and lactose acceptor (2 mM) for 20 min at 30 °C in 13 mM HEPES buffer (pH 7.0). Each experiment was carried out in triplicate.
Table 2
Pre-incubation protocols and enzyme turnovers.
Pre-incubation protocol Turnover (%) Turnover is defined as the percentage consumption of donor UDP-Gal in the biochemical assay, relative to the total amount of UDP-Gal used.
For the two inhibitors 2 and 3, inhibitory activity increased consistently with increasing pre-incubation time, albeit at different rates, before reaching a plateau after 60 mins (2) and 20 mins (3), respectively ( Fig. 8 & Table 3 ). The covalent mode of action for 2 and 3 was further confirmed with several key experiments, as for the parent compound 1. Thus, for both 2 and 3, covalent adducts with LgtC were detected by mass spectrometry (Fig. 3B & C) , and the time-dependent formation of a covalent adduct with cysteine was observed by 1 H NMR (SI). In control experiments, neither 2 nor 3 showed activity against CIP or -1,4-GalT (SI).
Figure 8
LgtC inhibition by pyrazolones 2 and 3 at different pre-incubation times. For conditions and IC 50 values see Table 3 .
Table 3
LgtC inhibition by pyrazolones 2 and 3 at different pre-incubation times. IC 50 values extracted from inhibition curves in Figure 8 . (28 µM) were added, and the reactions were incubated for 20 min at 30 °C. Enzyme activity was determined under standard assay conditions. Each experiment was carried out in triplicate.
The activity of a covalent inhibitor is governed by two parameters: the strength of the initial, non-covalent binding interaction with the target enzyme, and the reactivity of the electrophilic warhead (Fig. 9) . In order to dissect the contribution of these two steps towards the overall activity of 2 and 3, we determined k obs at different inhibitor concentrations. By plotting k obs over inhibitor concentration, the kinetic parameters for the first (K i ) and second (k inact ) interaction step can be extracted [13] . This analysis shows that k inact for both 2 and 3 is of a similar order of magnitude, whereas K i is about 10-times greater for compound 2 than for 3. These results suggest that due to the different substitution pattern of the 4-substituent, 2 and 3 differ significantly in their noncovalent binding affinity for LgtC, but not so much in the reactivity of the Michael acceptor system. This profile corresponds to the results from experiments with different pre-incubation times, which show that 2 requires a longer pre-incubation period for maximal activity than 3 ( Table 3 ). The different non-covalent affinities of 2 and 3 are also consistent with the slightly different binding modes that were obtained for both inhibitors from covalent docking simulations. These docking results suggest that both 2 and 3 can bind at the substrate binding site of LgtC in an orientation that allows a covalent reaction with residue Cys246, but that the smaller 3-bromo-4-methoxyphenyl substituent in 3 can be more readily accommodated than the bulky 3-benzyloxyphenyl substituent in 2 (SI, Fig. S1 ).
Figure 9
Covalent inhibition kinetics for 2 and 3. . From these plots, K i and k inact were obtained as previously described [13] . All experiments were performed in triplicate.
Conclusions
Existing inhibitors of the bacterial α-1,4-galactosyltransferase LgtC are substrate analogues based on a sugar-nucleotide scaffold [18, 26] . Our results establish suitably substituted pyrazol-3-ones as the first non-substrate-like, covalent inhibitor chemotype for this enzyme. The activity of inhibitors 2 and 3 upon preincubation is comparable to the most potent substrate-based LgtC inhibitors reported to date [26] . Our data suggest that pyrazol-3-ones 1-3 bind at the substrate binding site of LgtC prior to the covalent reaction, which most likely occurs at the non-catalytic residue Cys246 in the enzyme active site. Importantly, the new inhibitors are inactive against three related GTs that use either the same donor or acceptor substrate as LgtC, but lack a non-catalytic cysteine in the active site. This behaviour is notable, as other pyrazol-3-ones have previously been classified as non-selective, pan-assay interfering compounds (PAINS) [27] . It suggests that, while it is likely that the unoptimised inhibitors 1-3 may also react with other proteins that contain a carbohydrate-or nucleotide-binding site with a non-catalytic cysteine, target selectivity could be engineered into these inhibitors through further structural modification.
Non-catalytic cysteine residues are a common feature of bacterial GTs. In principle, the direct targeting of non-catalytic cysteines can therefore serve as a general inhibitor discovery strategy against many other bacterial GTs. In the sequence-based CAZy database of carbohydrate-active enzymes [28] , LgtC is a member of family GT-8.
Neisseria meningitidis LgtC is the only bacterial member of this CAZy family for which structural information is currently available. Sequence alignment with other members of
CAZy family GT-8 shows that Cys246 in LgtC is part of a highly conserved 6-aa motif, which is present in several other GTs from different bacteria (SI, Fig. S2 ). Interestingly, these enzymes are not limited to galactosyltransferases, but also include GTs with other substrate specificities as well as GTs with unknown function.
Beyond family GT-8, structural information is currently available for a total of 48
GTs from bacterial organisms that have a human host. 23 of these structures, including Neisseria meningitidis LgtC, have been solved at a resolution of <3Å and contain a ligand in the active site (SI, Table S3 ). Analysis of these 23 structures reveals that all but three, across 14 different CAZy families, have a non-catalytic cysteine at or near the active site. In 11 of these structures, this cysteine is within 8Å of the active site ligand (see Fig. 10 for selected examples, and SI, Table S3 ). This analysis demonstrates that the presence of non-catalytic, active site cysteines is widespread in bacterial GTs from both Gram-negative and Gram-positive organisms, independent of enzyme substrate specificity, CAZy family, overall fold type and biological function (Fig. 10) .
Figure 10
Examples for bacterial GTs with non-catalytic active-site cysteines. 
D C F E B A
A representative example is the bifunctional CMP-Neu5Ac:α-2,3/-2,8-sialyltransferase Cst-II from Campylobacter jejuni [29] . In Cst-II, the non-catalytic cysteine residue Cys30 is located to the rear of active site, at a distance of 6.0Å from the CMP ligand (SI, Fig. S3 ). Cst-II is a member of CAZy family GT-42. Sequence alignments within this family suggest that Cys30 in Cst-II is part of a conserved 10-aa sequence, which is also present in several other bacterial sialyltransferases in this family (SI, Fig. S4 ).
This analysis, in conjunction with our experimental results, suggests that the presence of non-catalytic active site cysteines can be systematically exploited for the discovery of new inhibitor classes against a broad range of bacterial GTs, including enzymes with very different, or indeed unknown, substrate specificities. In the latter case, such inhibitors would be of considerable use to annotate the biochemical and biological function of these GTs. Our results provide a blueprint for such an inhibitor discovery strategy. Such a strategy will be facilitated further by the recent publication of freely available, web-based protocols for covalent docking [25] and virtual screening [30] .
Many of the bacterial GTs that are amenable to this general inhibitor discovery strategy are involved in bacterial virulence processes and complex pathogen/host interactions [31] . Covalent inhibitors would therefore be eminently useful as tool compounds for anti-virulence drug discovery [32] , not only for inhibition studies, but also as affinity probes for the labelling and imaging of bacterial GTs in vivo. In preliminary experiments, we have already successfully used a fluorescent derivative of 1 for the labelling of LgtC (unpublished results). Results from this ongoing work will be reported in due course.
Experimental section
Chemistry
All chemical reagents were obtained commercially and used as received. Target compounds and synthetic intermediates were purified by flash chromatography column and characterized by TLC, Phenyl-3-(trifluoromethyl)-1H-pyrazol-5-ol (7) . The title compound [34] 
1-
(Z)-5-Methyl-2-phenyl-4-(2-(trifluoromethyl)benzylidene)-2,4-dihydro-3H-pyrazol-3-
one (1). 6 (220 mg, 2.03 mmol) and 2-(trifluoromethyl)benzaldehyde (706 mg, 4.06 mmol) were dissolved in glacial acetic acid. The reaction was heated to reflux until TLC (hexane/EA 3:1) showed complete consumption of starting material. The reaction mixture was cooled and the product was isolated by column chromatography. The title compound was obtained as an orange solid (320 mg, 0.97 mmol, 48%). 
(Z)-4-(3-(Benzyloxy)benzylidene)-2-phenyl-5-(trifluoromethyl)-2,4-dihydro-3H-
pyrazol-3-one (2 
(Z)-4-(3-Bromo-4-methoxybenzylidene)-2-phenyl-5-(trifluoromethyl)-2,4-dihydro-3H-pyrazol-3-one (3)
.
Biochemistry.
LgtC was expressed and purified as previously described [26] .
Recombinant LgtC was activated with DTT (10 mM, in HEPES buffer) in a 1:1 ratio for 30 min at 30 °C prior to each experiment, unless otherwise stated. For enzyme activity
and inhibition experiments, we used a recently reported modification [20] of a colorimetric glycosyltransferase assay originally developed by Wu and co-workers [35] .
All assays were carried out in Nunc clear, flat-bottom 96-well microplates, unless otherwise stated.
Inhibition assays.
For IC 50 experiments, LgtC activity was adjusted to 20-50% turnover of UDP-Gal donor. We have previously shown that within this turnover range IC 50 values are obtained reproducibly [20] . Assay components were added in the order required for the respective experiment (Methods A-D). All concentrations for the assay components are final concentrations. 
Method
Inhibition kinetics.
The kinetic parameters k obs , K i and k inact for covalent inhibition by 2 and 3 were determined with the assay protocols described above, following the general approach described by Singh and co-workers [13] . LgtC activity was determined 6) to obtain the values for K i and k inact as previously described [13] . All experiments were performed in triplicate. 
